

Greater Manchester Joint Formulary & RAG/DNP list change log

26 January 2024

The list below includes changes made in the last 12 months. For information on older updates, contact nuth.enquiries.gmmmg@nhs.net



Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
26/01/2024	6	6.1.1.2	Links to NICE Key Therapeutic Topics 12 & 20 deleted (KTTs retired by NICE).	n/a	Y	9.27
26/01/2024	6	6.3.2	Prednisolone 2.5mg & 5mg enteric coated tablets removed from DNP list	Y	Y	9.27
26/01/2024	5	5.3	Tocilizumab added as RED for COVID-19, as per NICE TA878	Y	Y	7.8
26/01/2024	5	5.3	Casirivimab / imdevimab for COVID-19 removed from formulary & RAG following as per NICE TA878	n/a	Y	7.8
26/01/2024	RAG		Mavacamten added as RED, as per NICE TA 913	Y	n/a	n/a
14/01/2024	2	2.8	Edoxaban entry amended to reference to remove retired statement on GM DOAC statement	n/a	Y	7.23
22/12/2023	2	2.8.2	Apixaban made first choice DOAC in NVAF. No change in other indications	n/a	Y	7.22
22/12/2023	3	3.2	Fostair MDI replaced by Luforbec MDI	n/a	Y	8.10
22/12/2023	9		DNP entry for herbal medicines updated to include other natural products, in line with NHSE guidance on products not	Y	Y	6.8
22/12/2023	12	12.1.2	Added link to NG233, otitis media with effusion in under 12s.	n/a	Y	5.1
22/12/2023	RAG		Cipaglucosidase alfa for Pompe disease added as RED, as per NICE TA912	Y	n/a	n/a
20/12/2023	10	10.1.3	Link to rituximab biosimilar statement deleted - statement no longer available.	n/a	Y	7.18
20/12/2023	10	10.1.4	Lesinurad deleted - no longer marketed	Y	Y	7.18
20/12/2023	10	10.2.2	Nusinersen formulation information corrected	n/a	Y	7.18
20/12/2023	10	10.3.2	Link to GMMMG neuropathic pain guideline updated	n/a	Y	7.18
18/12/2023	4	4.7.4.2	Rimegepant for preventing migraine added as GREEN (following specialist initiation) as per NICE TA906.	Y	Y	9.22
18/12/2023	4	4.7.4.2	Link added to GMMMG headache pathway	n/a	Y	9.22
18/12/2023	11	11.8.1	Sodium chloride 5% eye drops updated to GREEN (following specialist advice) for management of corneal oedema. Previously RED.	Y	Y	5.7
04/12/2023	2	2.12	Bempedoic acid updated to GREEN (from green following specialist advice). Links added to national lipid guidance and national statin intolerance pathway	Y	Y	7.21
04/12/2023	4	4.2.3, 4.8.	MHRA DSU added: Valproate: dispense full packs of valproate-containing medicines	n/a	Y	9.21
04/12/2023	11	11.4.1	Betamethasone, dexamethasone, prednisolone and fluorometholone eye drops assigned GREEN (following specialist initiation) RAG status	Y	Y	5.6
04/12/2023	13	13.5.1	MHRA DSU added: Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight of	n/a	Y	6.10
04/12/2023	DNP		Semaglutide for obesity in 12-17 year olds, as per NICE TA910	Y	n/a	
15/11/2023	RAG		Tolvaptan entries corrected: incorrect entry for polycystic kidney disease deleted, information merged with other ICS-commissioned entry (SIADH not requiring chemotherapy)	Y	n/a	n/a
09/11/2023	1	1.5.3	Upadacitinib for previously treated moderately to severely active Crohn's disease added as RED, as per TA905	Y	Y	7.11
09/11/2023	2	2.12	MHRA DSU link added: Statins: very infrequent reports of myasthenia gravis (Sept 2023)	n/a	Y	7.20
09/11/2023	2	2.5.5.1	Dapagliflozin for chronic heart failure with preserved or mildly reduce ejection fraction added as GREEN (following	Y	Y	7.20
09/11/2023	3	3.4.2	Link added to omalizumab for chronic inducible urticarias commissioning statement (unlicensed)	n/a	Y	8.9
09/11/2023	13	13.5.3	Deucravactinib for moderate to severe plaque psoriasis added as per NICE TA907	Y	Y	6.9
01/11/2023	4	4.3.4	DNP entry for esketamine amended to add link to terminated NICE TA899 for major depressive disorder with imminent	Y	Y	9.20

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
01/11/2023	5	5.3.3	Bulvertide added as RED, as per NICE TA896	Y	Y	7.7
01/11/2023	RAG		Link to NICE CG57 added to paediatric RAG list entry for emollient bath additives.	Y	n/a	n/a
30/10/2023	13	13.4	Error corrected - hydrocortisone 0.5% cream removed from DNP list, replaced with 0.5% ointment	Y	n/a	n/a
05/10/2023	1	1.5.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Vedolizumab SC solution added as RED, for use as per other vedolizumab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Risankizumab for Crohn's disease added as RED, as per NICE TA888.	n/a	Y	7.10
05/10/2023	2	2.2, 2.4	Links to NICE CG127 removed and replaced with links to NG136, which superseded it.	n/a	Y	7.19
05/10/2023	6	6.1.2.3	Links to NG18 added alongside liraglutide, dulaglutide, empagliflozin	n/a	Y	9.26
05/10/2023	10	10.1.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.17
05/10/2023	13	13.4	Hydrocortisone 0.5% cream and 2.5% cream and ointment added to DNP list (criterion 2)	Y	Y	6.8
02/10/2023	8	8.2.2	Voclosporin added as RED, as per NICE TA882	Y	Y	12.7
02/10/2023	13	13.1	Difelikefalin added as RED, as per NICE TA890	Y	Y	6.7
28/09/2023	1	1.2	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia (July 2023)	n/a	Y	7.9
28/09/2023	1	1.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	7.9
28/09/2023	4	4.6	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of	n/a	Y	9.19
28/09/2023	4	4.2.3 &	MHRA DSU link added: Valproate: re-analysis of study on risks in children of men taking valproate (August 2023)	n/a	Y	9.19
28/09/2023	8	8	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions	n/a	Y	12.6
28/09/2023	10	10.1.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	7.16
28/09/2023	13	13.5.1 & 13.5.2 & 13.6.2	MHRA DSU link added: Oral retinoid medicines ▼ : revised and simplified pregnancy prevention educational materials for healthcare professionals and women (July 2019)	n/a	Y	6.6
28/09/2023	13	13.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions	n/a	Y	6.6
15/09/2023	6	6.1	Links added to GM guidance on managing GLP-1 shortages in T2DM	Y	Y	9.25
01/09/2023	2	2.5	Link added to new GMMMG hypertension pathway	n/a	Y	7.17
01/09/2023	3	3.4.2	Tezepelumab added as RED as per NICE TA880: Tezepelumab for treating severe asthma	Y	Y	8.8
01/09/2023	6	6.1.1.2	Statements on GLP-1 shortages added to the intermediate, long-acting and biphasic insulin sections, with links SPS	n/a	Y	9.24
01/09/2023	6	6.1.1.2	Toujeo updated to GREEN (was previously green specialist advice and GREY) to support management of GLP-1	Y	Y	9.24
01/09/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.24
01/09/2023	6	6.1.1.3	Insulin need cost chart updated	n/a	Y	9.24
01/09/2023	6	6.1.2.3	Statement on GLP-1 shortages added to the GLP-1 section, with cross-reference to insulin section and link to SPS	n/a	Y	9.24
01/09/2023	RAG		Fosfomycin for uncomplicated UTI changed to GREEN (was green specialist advice)	Y	n/a	n/a

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
23/08/2023	6	6.1.6	Dexcom ONE and Freestyle Libre 2 added to formulary	n/a	Y	9.23
07/08/2023	2	2.2.3	Finerenone added as GREEN (specialist advice) for CKD in type 2 diabetes, as per NICE TA877.	Y	Y	7.16
07/08/2023	4	4.5.1	Semaglutide injection added as RED, for prescribing by specialist weight management services only as per NICE TA875: Semaglutide for managing overweight and obesity	Y	Y	9.18
07/08/2023	4	4.7.2	Actimorph - add as GREEN and GREY, as an alternative to morphine sulfate tablets or oral solution 10mg/5ml	Y	Y	9.18
07/08/2023	4	4.7.4.2	Eptinezumab added as RED as per NICE TA871: Eptinezumab for preventing migraine	Y	Y	9.18
07/08/2023	6	6.3.2	Efmody added as Green (following specialist initiation) as an alternative option, only for patients not well controlled on	Y	Y	9.22
07/08/2023	RAG		Dapagliflozin added to paediatric RAG list for CKD 2-3 as RED	Y	n/a	n/a
28/07/2023	2	2.12	Typo corrected: bempedoic acid amended to Greep (specialist advice), aligning with CRG decision and RAG list	n/a	Y	7.15
28/07/2023	3	3.4.3	MHRA DSU link added: Adrenaline auto-injectors (AAIs): new guidance and resources for safe use, June 2023	n/a	Y	8.7
28/07/2023	4	4.1 & 4.7	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy, June 2023	n/a	Y	9.17
28/07/2023	4	4.8.1	Link added to NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex	n/a	Y	9.17
28/07/2023	5	5.1.7	Bezlotoxumab entry amended to remove link to retired HCD commissioning statement	Y	Y	7.6
28/07/2023	9	9.2.1.1	MHRA DSU link added: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in	n/a	Y	6.7
28/07/2023	10	10.1.1	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after	n/a	Y	7.15
28/07/2023	RAG		Chloral hydrate and cloral betaine added as RED	Y	n/a	n/a
28/07/2023	RAG		Asfotase alfa added as RED as per NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia	Y	n/a	n/a
29/06/2023	2	2.9	Note added: "do not routinely offer aspirin for primary prevention of CVD", with link to CG181.	n/a	Y	7.14
29/06/2023	6	6.5.1	Somatrogon added as RED (pending shared care) as per NICE TA863	Y	Y	9.21
29/06/2023	10	10.1.3	NICE TA861, upadacitinib for non-radiographic axial spondyloarthritis, added as RED	Y	Y	7.14
29/06/2023	RAG		Vutisiran added as RED, as per NICE TA868	Y	n/a	n/a
29/06/2023	RAG		Ataluren added as RED, as per NST 22	Y	n/a	n/a
12/06/2023	6	6.1.2.2	Metformin 1g immediate-release tablets added to DNP list, criterion 2	Y	Y	9.20
06/06/2023	RAG		Typo corrected: upadacitinib TA856 corrected to read ulcerative colitis	Y	n/a	n/a
26/05/2023	1	1.5.3	Upadacitinib added as RED, in line with TA856	Y	Y	7.8
26/05/2023	1	1.5.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events,	n/a	Y	7.8
26/05/2023	1	Misc	IQoro neuromuscular training device added to DNP list, criterion 1	Y	Y	7.8
26/05/2023	2	2.12	Colestyramine and colesevelam for CVD prevention in hyperlipidaemia added to grey list as green (specialist advice),	Y	Y	7.13

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
26/05/2023	5	5.3.2.2	Maribavir added as RED, in line with TA860	Y	Y	7.5
26/05/2023	6	6.1	Following preparations removed from formulary following discontinuation:	n/a	Y	6.19
26/05/2023	10	10.1.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events,	n/a	Y	7.13
26/05/2023	13	13.11.6	Potassium permanganate assigned RED RAG status	Y	Y	6.5
26/05/2023	13	13.5.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events,	n/a	Y	6.5
26/05/2023	13	13.6.1	Trifarotene for acne added to formulary as GREEN	Y	Y	6.5
26/05/2023	13	13.6.2	MHRA DSU link added: Isotretinoin (Roaccutane ▼): new safety measures to be introduced in the coming months,	n/a	Y	6.5
24/05/2023	RAG		RAG list updated to add sotrovimab, to align with formulary entry added in May 2022.	Y	n/a	n/a
24/04/2023	4	4.10.1	Links to NICE guidance updated to correct broken link.	n/a	Y	9.15
24/04/2023	4	4.3.4	Esketamine nasal spray added to DNP list, as per NICE TA854: Esketamine nasal spray for treatment-resistant	Y	Y	9.15
24/04/2023	6	6.2.1	Link added to NICE NG230: Thyroid cancer: assessment and management	n/a	Y	9.18
24/04/2023	6	6.4.1	Link added to Joint BMS FSRH RCGP RCOG SfE and RCN Women's Health Forum safety alert on doses of oestrogen exceeding product licenses.	n/a	Y	9.18
24/04/2023	9	9.1.4	Link added to NICE TA853, avatrombopag for primary chronic immune thrombocytopenia	Y	Y	6.6
16/03/2023	1	1.5.3	Ozanimod for UC added as RED, in line with NICE TA828	Y	Y	7.7
16/03/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.16
16/03/2023	6	6.1.1.3	Insulin needle cost chart updated	n/a	Y	9.16
16/03/2023	6	6.4.2	MHRA DSU link added: Topical testosterone (Testogel): risk of harm to children following accidental exposure. Jan	Y	Y	9.16
16/03/2023	6	6.7.2	Reulgolix/estradiol/norethisterone for fibroids added as GREEN (specialist advice) in line with NICE TA832	Y	Y	9.16
16/03/2023	10	10.1.3	Upadacitinib for active AS added as RED, in line with NICE TA829	n/a	Y	7.11
16/03/2023	11	11.4.1	Links to TA349 (dexamethasone for DMO) removed and replaced with links to TA824	n/a	Y	5.5
16/03/2023	RAG		Avacopan added as RED, in line with NICE TA825	Y	n/a	n/a
21/02/2023	9	9.1.4	Fostamatinib removed from DNP list and added to formulary as a RED drug, in line with NICE TA835	Y	Y	6.5
21/02/2023	10	10.1.1	Links to CG177 removed and replaced with links to updated guidance NG226.	n/a	Y	7.10
21/02/2023	10	10.1.5	Links to CG177 removed and replaced with links to updated guidance NG226. Advice on glucosamine and chondroitin replaced with updated advice on glucosamine and opioids.	n/a	Y	7.10
21/02/2023	RAG		MHRA DSU link added: Xaquia (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations	Y	n/a	n/a